6-Methoxydihydrosanguinarine
Based on 1 Customer Validation
6-Methoxydihydrosanguinarine is an alkaloid with activity across multiple cancer cell types. 6-Methoxydihydrosanguinarine activates IRE1/JNK signaling, blocks Akt/mTOR and PI3K/AKT/mTOR pathways, reduces expression of Cdc25C, CyclinB1, Cdc2, YAP/TAZ, Survivin, GPX4, and EGFR, upregulates IRE1 and DR5, and activates JNK and caspases. 6-Methoxydihydrosanguinarine induces apoptosis, G2/M phase arrest, DNA damage, ROS generation, lipid peroxidation, ferroptosis, autophagy, and suppresses cancer cell growth. 6-Methoxydihydrosanguinarine disruptes the biofilm formation of Candida albicans (C. albicans). 6-Methoxydihydrosanguinarine can be used for the research of non-small cell lung cancer, hepatocellular carcinoma, melanoma, colon carcinoma, ovarian cancer and breast cancer.
For research use only. We do not sell to patients.
- Purity: 99.88%
- CAS No.: 72401-54-8
- Formula: C21H17NO5
- Molecular Weight:363.36
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
All YAP Isoforms
More
Biological Activity
IC50: 0.61 μM (MCF-7 cells)IC50: 0.54 μM (SF-268 cells)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
1.59 μM
Compound: 8j
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 33479636] |
| NCI-H1975 | IC50 |
1.17 μM
Compound: 8j
|
Antiproliferative activity against human H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 33479636] |
6-Methoxydihydrosanguinarine (0.15625-10 μM; 24 h) suppresses the viability of A549 and H1299 NSCLC cells in a dose-dependent manner, with IC50 values of 2.154 μM and 2.586 μM respectively after 24 h treatment[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) induces G2/M phase arrest in A549 and H1299 NSCLC cells after 24 h treatment at 2 μM, and G1 phase arrest in H1299 cells at lower concentrations[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) downregulates cell cycle-related proteins Cdc25C, p-Cdc25C, cyclinB1, and Cdc2 in A549 and H1299 NSCLC cells after 24 h treatment[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) dose-dependently activates the caspase cascade and induces PARP cleavage in A549 and H1299 NSCLC cells after 24 h treatment, promoting apoptotic cell death[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) dose-dependently inhibits the Akt/mTOR signaling pathway in A549 and H1299 NSCLC cells after 24 h treatment by reducing Akt and p70S6K phosphorylation and total protein levels[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) dose-dependently blocks the YAP/TAZ oncogenic signaling axis in A549 and H1299 NSCLC cells after 24 h treatment by reducing YAP, TAZ, and survivin expression and increasing LATS1/2 phosphorylation[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) dose-dependently induces apoptosis in A549 and H1299 NSCLC cells after 24 h treatment[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 12 h) dose-dependently elevates intracellular ROS levels in A549 and H1299 NSCLC cells after 12 h treatment[1].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) dose-dependently activates the IRE1/JNK signaling pathway in A549 and H1299 NSCLC cells after 24 h treatment[1].
6-Methoxydihydrosanguinarine (0.125-8 μM; 24 h) dose-dependently reduces cell viability in HepG2 and Huh7 cells, with IC50 values of 2.83 μM and 3.46 μM after 24 h of treatment[2].
6-Methoxydihydrosanguinarine hydrochloride (6-MS) (1-2 μM; 12 h) dose-dependently increases intracellular ROS production in HepG2 and Huh7 cells after 12 h of treatment[2].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) dose-dependently inhibits the EGFR/Akt signaling pathway, as measured by reduced EGFR expression and Akt phosphorylation, in HepG2 and Huh7 cells after 24 h of treatment[2].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) activates the JNK and p38MAPK pathways in HepG2 and Huh7 cells after 24 h of treatment, with JNK activation being required for 6-MS-induced PARP cleavage (a marker of apoptosis)[2].
6-Methoxydihydrosanguinarine (0.5-2 μM; 24 h) dose-dependently upregulates DR4 and DR5 expression in HepG2 and Huh7 cells after 24 h of treatment, and DR5 upregulation is required for 6-Methoxydihydrosanguinarine hydrochloride-mediated sensitization to TRAIL-induced apoptosis[2].
6-Methoxydihydrosanguinarine (0-1.5 μM; 12 h) potently inhibits the viability of HLE and HCCLM3 hepatocellular carcinoma cells with IC50 values of 1.129 μM and 1.308 μM respectively after 12 h, and is less cytotoxic to normal LX-2 hepatic stellate cells[3].
6-Methoxydihydrosanguinarine (1 μM (HLE), 1.5 μM (HCCLM3); 12 h) induces cell death in hepatocellular carcinoma cells after 12 h of treatment, and this effect is mediated via ferroptosis, as shown by reversal with ferroptosis inhibitors[3].
6-Methoxydihydrosanguinarine (1 μM (HLE), 1.5 μM (HCCLM3); 6 h) downregulates GPX4 expression at the transcriptional level in hepatocellular carcinoma cells after 6 h of treatment[3].
6-Methoxydihydrosanguinarine (1-50 μM; 24 h) selectively inhibits human A375 melanoma cell viability over normal NHDF cells, with an IC50 of 2.85 μM after 24 h[4].
6-Methoxydihydrosanguinarine (0-32 μM; 24 h) potently reduces MCF-7 breast cancer cell viability in a time- and dose-dependent manner, with an IC50 of 4.21 μM after 24 h[5].
6-Methoxydihydrosanguinarine (2-4 μM; 6-24 h) induces apoptosis in MCF-7 breast cancer cells by upregulating pro-apoptotic proteins and downregulating anti-apoptotic proteins, induces autophagy by upregulating autophagy-related proteins, and inhibits the PI3K/AKT/mTOR pathway by reducing phosphorylation of key pathway proteins[5].
6-Methoxydihydrosanguinarine downregulates the expression of EFG1, CDC35, RAS1, and TPK2, all of which are critical components of the cAMP pathway. Furthermore, 6-Methoxydihydrosanguinarine changes the membrane permeability of C. albicans and caused reactive oxygen species accumulation, leading to cell death[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549, H1299 non-small cell lung cancer (NSCLC) cells
-
Concentration:0.15625 μM, 0.3125 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM
-
Incubation Time:24 h
-
Result:Caused a dose-dependent reduction in cell viability in both cell lines, with IC50 values of 2.154 μM for A549 cells and 2.586 μM for H1299 cells.
-
Cell Line:A549, H1299 non-small cell lung cancer (NSCLC) cells
-
Concentration:0.5 μM, 1 μM, 2 μM
-
Incubation Time:24 h
-
Result:Induced G2/M phase arrest in both A549 and H1299 cells at 2 μM, with a concomitant reduction in G1 or S phase cells.
Induced G1 phase block in H1299 cells at lower concentrations.
-
Cell Line:A549, H1299 non-small cell lung cancer (NSCLC) cells
-
Concentration:0.5 μM, 1 μM, 2 μM
-
Incubation Time:24 h
-
Result:Significantly decreased the protein levels of Cdc25C, p-Cdc25C, cyclinB1, and Cdc2 in both cell lines.
Significantly increased the protein levels of γ-H2AX in both A549 and H1299 cells, indicating induction of DNA double-strand breaks.
Caused a dose-dependent increase in the cleavage of caspase-3, caspase-8, caspase-9, and PARP in both A549 and H1299 cells.\nCaused a dose-dependent decrease in protein expression of p-Akt, total Akt, p-p70S6K, and total p70S6K in both A549 and H1299 cells, indicating inhibition of the Akt/mTOR pathway.
Caused a dose-dependent decrease in protein expression of YAP, TAZ, and survivin, and an increase in p-LATS1/2 protein expression in both A549 and H1299 cells, indicating inhibition of the YAP/TAZ oncogenic axis.
-
Cell Line:Human breast cancer MCF-7 cells
-
Concentration:2 μM, 4 μM
-
Incubation Time:6, 12, 24 h
-
Result:Increased cleaved caspase-7/caspase-7, cleaved PARP/PARP, and BAX expression, and decreased Bcl-2 expression, in dose- and time-dependent manners.
Increased LC3 II/LC3 I and Atg5 expression in dose- and time-dependent manners.
Decreased P-PI3K/PI3K, P-AKT/AKT, and P-mTOR/mTOR ratios in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c-nude mice (5-week-old) were injected subcutaneously ventrally CAOV3 cells (5×106)[7]
-
Dosage:5 mg/kg
-
Administration:i.p.; daily; 14 days
-
Result:The tumor volume and weight were much lower
Showed no physiologically harmful effects on mice.
Chemical Information
-
CAS No. 72401-54-8
-
Appearance Solid
-
Molecular Weight 363.36
-
Formula C21H17NO5
-
Color Off-white to pink
-
SMILES
CN1C2=C3C(C=C4OCOC4=C3)=CC=C2C5=C(C6=C(OCO6)C=C5)C1OC
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 12.5 mg/mL (34.40 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3.85 mg/mL (10.60 mM); Clear solution
This protocol yields a clear solution of ≥ 3.85 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (38.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (290 KB)
-
SDS (481 KB)
- English - EN (481 KB)
- Français - FR (481 KB)
- Deutsch - DE (481 KB)
- Norwegian - NO (481 KB)
- Español - ES (481 KB)
- Swedish - SV (481 KB)
- Italian - IT (481 KB)
- Korean - KR (481 KB)
- Portuguese - PT (481 KB)
-
Handling Instructions (2659 KB)
References
[1]. Liu Y, et al. Activity of 6-methoxydihydrosanguinarine from Hylomecon japonica against wild-type and fluconazole-resistant Candida albicans biofilms. J Asian Nat Prod Res. 2025 Jul 28:1-12. [Content Brief]
[2]. Zhang H, et al. A novel mechanism of 6-methoxydihydroavicine in suppressing ovarian carcinoma by disrupting mitochondrial homeostasis and triggering ROS/ MAPK mediated apoptosis. Front Pharmacol. 2023 May 5;14:1093650. [Content Brief]
[3]. Qi X, et al. 6-Methoxydihydrosanguinarine Suppresses the Proliferation of Non-small Cell Lung Cancer Cells through Elevation of ROS and Activation of IRE1/JNK Signaling. Cell Biochem Biophys. 2025 Dec;83(4):5307-5319. [Content Brief]
[4]. Wang LL, et al. 6-Methoxydihydrosanguinarine exhibits cytotoxicity and sensitizes TRAIL-induced apoptosis of hepatocellular carcinoma cells through ROS-mediated upregulation of DR5. Med Oncol. 2023;40(9):266. Published 2023 Aug 11. [Content Brief]
[5]. Han L, et al. Bioactive natural alkaloid 6-Methoxydihydrosanguinarine exerts anti-tumor effects in hepatocellular carcinoma cells via ferroptosis. Front Pharmacol. 2025;16:1500461. Published 2025 Apr 24. [Content Brief]
[6]. Zuo C, et al. Molecular interactions between fibrinogen and 6-methoxydihydrosanguinarine and their modulation of anticancer activity in melanoma A375 cells. Int J Biol Macromol. 2025;307(Pt 4):142170. [Content Brief]
[7]. Zhang L, et al. 6-Methoxydihydrosanguinarine induces apoptosis and autophagy in breast cancer MCF-7 cells by accumulating ROS to suppress the PI3K/AKT/mTOR signaling pathway. Phytother Res. 2023;37(1):124-139. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7521 mL | 13.7605 mL | 27.5209 mL | 68.8023 mL |
| 5 mM | 0.5504 mL | 2.7521 mL | 5.5042 mL | 13.7605 mL | |
| 10 mM | 0.2752 mL | 1.3760 mL | 2.7521 mL | 6.8802 mL | |
| 15 mM | 0.1835 mL | 0.9174 mL | 1.8347 mL | 4.5868 mL | |
| 20 mM | 0.1376 mL | 0.6880 mL | 1.3760 mL | 3.4401 mL | |
| 25 mM | 0.1101 mL | 0.5504 mL | 1.1008 mL | 2.7521 mL | |
| 30 mM | 0.0917 mL | 0.4587 mL | 0.9174 mL | 2.2934 mL |
6-Methoxydihydrosanguinarine Related Classifications
HY-N3000 Related Classifications
Powered by Bioz